

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listing, of claims in the application.

**Listing of Claims:**

1. (Original) A method for preparing an tracer composition comprising:  
  
obtaining a  $^{13}\text{C}$  labeled Krebs cycle metabolite precursor that will produce an analyte;  
  
obtaining a deuterium source; and  
  
wherein gluconeogenesis is measured from a subject that was provided the precursor and the deuterium source, and produced the analyte, by comparison of the relative nuclear magnetic resonance profiles of the labeled components in the analyte.
2. (Original) The method of claim 1, wherein the analyte is  $^{13}\text{C}$ -glucose.
3. (Original) The method of claim 1, wherein the precursor is glucose, lactose, lactate or alanine.
4. (Original) The method of claim 1, wherein the deuterium source is deuterated water.
5. (Original) The method of claim 1, wherein the analyte is glucose deuterated in the 2, 5 and 6 positions, and any transformation that maintains the 2,5 and 6 positions in relation to one another.
6. (Original) The method of claim 1, wherein the analyte is (1-6  $^{13}\text{C}_2$ )-glucose.
7. (Original) The method of claim 1, wherein the water is  $\text{D}_2\text{O}$ .

8. (Original) The method of claim 1, wherein the flux is measured from blood, urine or tissue extracts.

9. (Original) The method of claim 1, wherein the analyte is  $^{13}\text{C}$ -labeled glucose with the label at the 2 or 5 positions, or at both positions.

10. (Original) The method of claim 9, wherein the metabolite is a transformation of the labeled glucose containing the labeled 2 position, or the labeled 5 position, or both.

11. (Original) The method of claim 1, further comprising the step of adding  $^{13}\text{C}_3$ -propionate.

12. (Original) The method of claim 1, wherein the Krebs cycle precursor is selected from the group consisting of pyruvic acid, acetic acid, acetoacetic acid, beta-hydroxybutyric acid, a Krebs cycle pathway metabolite, and mixtures thereof.

13. (Original) The method of claim 1, wherein the analyte is selected from the group consisting of pyruvic acid, acetic acid citric acid, isocitric acid, cis-aconitic acid, 2-ketoglutaric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof.

14. (Original) A method for preparing an tracer composition comprising:  
  
obtaining a deuterium source;

wherein gluconeogenesis is measured from a subject that was provided the deuterium source, and produced an analyte, by comparison of the relative nuclear magnetic resonance profiles of the deuterium components in the analyte.

15. (Original) The method of claim 14, wherein the deuterium source is deuterated water.

16. (Original) The method of claim 14, wherein the analyte is glucose deuterated in the 2, 5 and 6 positions, and any transformation that maintains the 2,5 and 6 positions in relation to one another.

17. (Original) The method of claim 14, wherein the analyte is (1-6  $^{13}\text{C}_2$ )-glucose.

18. (Original) The method of claim 14, wherein the flux is measured from blood, urine or tissue extracts.

19. (Original) The method of claim 14, wherein the analyte is selected from the group consisting of pyruvic acid, acetic acid citric acid, isocitric acid, cis-aconitic acid, 2-ketoglutaric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof.

20. (Original) A method for preparing an isotopic metabolic flux tracer composition comprising:

providing a  $^{13}\text{C}$  labeled Krebs cycle metabolite precursor to a subject to produce an analyte;

obtaining a sample from the subject; and

measuring the nuclear magnetic resonance of the labeled tracers to determine the rate of gluconeogenesis.

21. (Original) The method of claim 20, wherein the analyte is  $^{13}\text{C}$ -glucose.

22. (Original) The method of claim 20, wherein the analyte is glucose labeled with  $^{13}\text{C}$  at positions 1 through 6, or combinations of two or more at any position.

23. (Original) The method of claim 20, wherein the analyte is (1-6  $^{13}\text{C}_2$ )-glucose.

24. (Original) The method of claim 20, wherein the sample is from blood, urine or tissue extracts.

25. (Original) The method of claim 20, further comprising the step of providing the subject with  $^{13}\text{C}_3$ -propionate.

26. (Original) The method of claim 20, wherein the Krebs cycle precursor is selected from the group consisting of pyruvic acid, acetic acid, acetoacetic acid, beta-hydroxybutyric acid, a Krebs cycle pathway metabolite, and mixtures thereof.

27. (Original) The method of claim 20, wherein the analyte is selected from the group consisting of pyruvic acid, acetic acid citric acid, isocitric acid, cis-aconitic acid, 2-ketoglutaric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof.

28. (Original) The method of claim 20, wherein the  $^{13}\text{C}$  Krebs cycle precursor is provided orally.

29. – 58. (Canceled).